Literature DB >> 20816942

Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells.

Andrea Mencarelli1, Marco Migliorati, Miriam Barbanti, Sabrina Cipriani, Giuseppe Palladino, Eleonora Distrutti, Barbara Renga, Stefano Fiorucci.   

Abstract

The pregnane-X-receptor (PXR) is master gene overseeing detoxification of wide number of xenobiotics and is critical for maintenance of intestinal integrity. The intestinal expression of genes involved in cellular detoxification is down-regulated in patients with inflammatory bowel diseases (IBD). Rifaximin is a non-absorbable antibiotic endowed with a PXR agonistic activity. In the present study we have investigated whether rifaximin activates PXR in primary human colon epithelial cells and human colon biopsies and assessed whether this antibiotic antagonizes the effect of tumor necrosis factor (TNF)-α on expression of PXR and PXR-related genes. Present results demonstrate that primary colon epithelial cells express PXR and that their exposure to rifaximin induces the expression of genes involved in cellular detoxification. Exposure to TNFα reduces the expression of PXR mRNA as well as expression of its target genes. This inhibitory effect was prevented by that co-treatment with rifaximin. Knocking down the expression of PXR in colon epithelial cells by an anti-PXR siRNA, abrogated the counter-regulatory effects exerted by rifaximin on cell exposed to TNFα. Finally, ex vivo exposure of colon biopsies obtained from ulcerative colitis patients to rifaximin increased the expression of genes involved in xenobiotics metabolism. In aggregate, these data illustrate that rifaximin increases the expression of PXR and PXR-regulated genes involved in the metabolism and excretion of xenobiotics and antagonizes the effects of TNFα in intestinal epithelial cells and colon biopsies. These non-antibiotic effects of rifaximin could contribute to the maintenance of the intestinal barrier integrity against xenobiotics and products generated by luminal bacteria.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816942     DOI: 10.1016/j.bcp.2010.08.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  39 in total

1.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

2.  Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.

Authors:  Pankajini Mallick; Sumit Basu; Bhagavtula Moorthy; Romi Ghose
Journal:  Toxicol In Vitro       Date:  2017-02-27       Impact factor: 3.500

3.  Constitutive androstane receptor regulates the intestinal mucosal response to injury.

Authors:  Grace M Hudson; Kyle L Flannigan; Sarah L Erickson; Fernando A Vicentini; Alexandra Zamponi; Christina L Hirota; Laurie Alston; Christophe Altier; Subrata Ghosh; Kevin P Rioux; Sridhar Mani; Thomas K Chang; Simon A Hirota
Journal:  Br J Pharmacol       Date:  2017-04-19       Impact factor: 8.739

Review 4.  The Roles of Xenobiotic Receptors: Beyond Chemical Disposition.

Authors:  Bryan Mackowiak; Jessica Hodge; Sydney Stern; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2018-05-14       Impact factor: 3.922

5.  Citrobacter rodentium Infection Inhibits Colonic P-glycoprotein Expression.

Authors:  Mitul Patel; Anoop Kumar; Dulari Jayawardena; Shubha Priyamvada; Arivarasu N Anbazhagan; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja; Seema Saksena
Journal:  Gene Rep       Date:  2019-10-31

6.  Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway.

Authors:  Wei Dou; Jingjing Zhang; Eryun Zhang; Aning Sun; Lili Ding; Guixin Chou; Zhengtao Wang; Sridhar Mani
Journal:  J Pharmacol Exp Ther       Date:  2013-03-27       Impact factor: 4.030

7.  Pregnane X Receptor Activation Attenuates Inflammation-Associated Intestinal Epithelial Barrier Dysfunction by Inhibiting Cytokine-Induced Myosin Light-Chain Kinase Expression and c-Jun N-Terminal Kinase 1/2 Activation.

Authors:  Aditya Garg; Angela Zhao; Sarah L Erickson; Subhajit Mukherjee; Aik Jiang Lau; Laurie Alston; Thomas K H Chang; Sridhar Mani; Simon A Hirota
Journal:  J Pharmacol Exp Ther       Date:  2016-07-20       Impact factor: 4.030

Review 8.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

Review 9.  Targeting xenobiotic receptors PXR and CAR for metabolic diseases.

Authors:  Jie Gao; Wen Xie
Journal:  Trends Pharmacol Sci       Date:  2012-08-10       Impact factor: 14.819

Review 10.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.